CTLA4 and neoplasm: In summary, TF is a promising natural small‐molecule compound for tumor immunotherapy, and when combined with an anti‐CTLA‐4 antibody, it shows a stronger ability to inhibit CRC cell growth, which in turn stimulates a more vigorous antitumor immune reaction.